Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer

Oncology

Volumn 56, Issue 4, 1999, Pages 301-307

  Fujita, Akihisa ^a,b   Takabatake, Hirotsugu ^a   Tagaki, Shigeru ^a   Sekine, Kyuhichiro ^a  

^a Minami ichijo Hospital   (Japan)

^b Minami ichijo Hospital   (Japan)

Author keywords

Irinocetan; Non small cell lung cancer; Phase I study; rhG CSF

Indexed keywords

CISPLATIN; IFOSFAMIDE; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032968354     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011982     Document Type: Article

References (13)

1. Hsiang YH, Hertzberg R, Hecht S, Liu LF: Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878.
2. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intra-cellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-1726.
3. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28: 4629-4638.
4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T, CPT-11 Lung Cancer Study Group: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated nonsmall-cell lung cancer. J Clin Oncol 1992;10: 16-20.
5. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992;10:1775-1780.
6. Nakagawa K, Fukuoka M, Niitani H, CPT-11 Lung Cancer Study Group: Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993;12: 332.
7. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hiroshima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M: Phase I study of irinotecan and cisptatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994;12:90-96.
8. Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A, Okamoto H, Nakashima H, Ohmatsu H, Shiraishi J, Nomura N, Saijo N: Phase I clinical trial of irinotecan, 7-ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 1994;54: 2636-2642.
9. Fujita A, Sasaki H, Mori T, Nakajima S, Sekine K, Inoue Y, Honda R, Asakawa M, Suzuki A: Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) for inoperable adenocarcinoma and large cell carcinoma of the lung. Jpn J Cancer Chemother 1991;18:51-55.
10. Fujita A, Takabatake H, Tagaki S, Sekine K: Phase I study of cisplatin, ifosfamide and CPT-11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer. Jpn J Cancer Chemother 1996;23:1285-1290.
11. World Health Organization: WHO Handbook for Reporting Results for Cancer Treatment. WHO Offset Publication. Geneva, World Health Organization, 1979, No 48.
12. Green S, Weiss G: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-253.
13. Sakata Y, Suzuki H, Kamataki T: Preventive effect of TJ-14, a Kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride. Jpn J Cancer Chemother 1994;21: 1241-1244.